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Cell proliferation and differentiation are interdependent processes. Here, we have
asked to what extent the two processes of neural progenitor cell amplification and
differentiation are functionally separated. Thus, we analyzed whether it is possible to
rescue a defect of terminal differentiation in progenitor cells of the dentate gyrus,
where new neurons are generated throughout life, by inducing their proliferation and/or
their differentiation with different stimuli appropriately timed. As a model we used the
Tis21 knockout mouse, whose dentate gyrus neurons, as demonstrated by us and
others, have an intrinsic defect of terminal differentiation. We first tested the effect
of two proliferative as well as differentiative neurogenic stimuli, one pharmacological
(fluoxetine), the other cognitive (the Morris water maze (MWM) training). Both effectively
enhanced the number of new dentate gyrus neurons produced, and fluoxetine also
reduced the S-phase length of Tis21 knockout dentate gyrus progenitor cells and
increased the rate of differentiation of control cells, but neither factor enhanced the
defective rate of differentiation. In contrast, the defect of terminal differentiation was
fully rescued by in vivo infection of proliferating dentate gyrus progenitor cells with
retroviruses either silencing Id3, an inhibitor of neural differentiation, or expressing
NeuroD2, a proneural gene expressed in terminally differentiated dentate gyrus neurons.
This is the first demonstration that NeuroD2 or the silencing of Id3 can activate the
differentiation of dentate gyrus neurons, complementing a defect of differentiation. It
also highlights how the rate of differentiation of dentate gyrus neurons is regulated
genetically at several levels and that a neurogenic stimulus for amplification of neural
stem/progenitor cells may not be sufficient in itself to modify this rate.
Keywords: hippocampal neurogenesis, neural differentiation, neural progenitor cells, NEUROD2, Id3, Tis21,
mouse models, neurogenic stimuli
INTRODUCTION
Cell proliferation and differentiation of neural stem and progenitor cells are correlated processes.
It is known that the cell cycle machinery exerts a direct role in fate determination and in the first
stages of differentiation (Hardwick et al., 2015) and, on the other hand, that several transcription
factors coordinately control both differentiation and cell cycle exit by regulating the expression
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of several cell cycle components (Lacomme et al., 2012).
Moreover, it has been proposed that variations of cell cycle length
regulate differentiation progression (Calegari and Huttner, 2003;
Calegari et al., 2005; Brandt et al., 2012). In fact, a positive
or negative modulation of the expression of cyclin D1, which
controls the G1 to S phase progression of the cell cycle, affects
the abundance of progenitor cells (Lange et al., 2009). However,
the amplification of neural stem cells triggered by cyclin
D1 overexpression is not sufficient to enhance the generation
of new neurons, unless the proliferative stimulus ceases after
amplification, in order to allow the process of differentiation
(Artegiani et al., 2011). This suggests that expansion and
differentiation of neural stem cells are correlated processes,
although the extent to which they are mutually interacting
remains open to investigation.
We have recently observed that ablation of the
antiproliferative transcriptional cofactor Tis21 (also known
as PC3 or Btg2), although increasing the proliferation of
progenitor cells of the dentate gyrus, paradoxically leads to
accumulation of early differentiated neurons, which cannot
terminally differentiate although they have already exited
the cell cycle (Farioli-Vecchioli et al., 2009). We and others
have demonstrated, by silencing Tis21, that Tis21 exerts on
neural cells of the dentate gyrus and subventricular zone an
intrinsic pro-differentiative action (Farioli-Vecchioli et al.,
2009, 2014a; Attardo et al., 2010). This Tis21 knockout-
dependent selective impairment of the terminal differentiation
suggests that this step is functionally separable from the cell
cycle.
The dentate gyrus of the hippocampus is a neurogenic niche
where new neurons are generated throughout adulthood from
putative neural stem cells with radial glial-like morphology,
identified by the expression of GFAP in their processes (Seri
et al., 2001), and expressing also nestin or Sox2 (defined as type-1
cells; Graham et al., 2003; Kempermann et al., 2004; Komitova
and Eriksson, 2004). Stem cells mature through successive
stages in proliferating progenitor cells, namely type-2ab and
type-3 cells. Type-2a and type-2b are both nestin positive, but
only the latter is positive for the immature neuronal marker
doublecortin (DCX), whereas type-3 cells express mainly DCX
(Filippov et al., 2003; Fukuda et al., 2003; Kronenberg et al.,
2003). Finally, progenitor cells attain the early postmitotic
stage of adult granule cell, characterized by the transient
expression of Ca-binding protein Calretinin (stage 5), which
is later replaced with Calbindin in mature granule cells (stage
6; Brandt et al., 2003; Steiner et al., 2004). The endogenous
Tis21 is expressed in type-2/type-3 progenitor cells and in
stage 6 (Calbindin-positive) terminally differentiated neurons,
but is absent in stage 5 neurons (Attardo et al., 2010), with a
pattern fully compatible with the stage 6-specific impairment
of maturation observed after ablation of Tis21. In fact, in the
absence of Tis21, stage 5 early postmitotic neurons cannot
differentiate into stage 6 neurons (Farioli-Vecchioli et al.,
2009).
In this report, our first aim has been to investigate the
relationship between proliferation and differentiation in dentate
gyrus adult neurons by analyzing whether the impairment of
terminal differentiation, elicited by Tis21 knockout, can be
reversed by a neurogenic stimulus inducing mainly proliferation
of progenitor cells, such as the inhibitor of serotonin reuptake,
fluoxetine. At the origin of our attempt was also the recent
finding that the proliferating stem cells (type-1, GFAP+) or
the committed progenitor cells (type-3, NeuroD1+) of the
hippocampus, divide faster accelerating the S-phase (Brandt
et al., 2012). The authors surmise the idea that once
stem/progenitor cells are activated, then they rapidly divide
and differentiate. This hypothesis is congruent with a previous
‘‘disposable stem cell’’ model, where a stem cell that has left
the quiescent state then rapidly travels toward a differentiated
state (Encinas et al., 2011); while it is in contrast with
previous findings indicating that the pool of expanding neural
stem and precursor cells in the cortex invests more time in
S-phase for quality control of DNA replication (Arai et al.,
2011).
Chronic treatment with fluoxetine efficiently stimulates
neurogenesis by selective targeting of the serotoninergic pathway
(Malberg et al., 2000; Santarelli et al., 2003; Encinas et al.,
2006). Fluoxetine has a neurogenic action less dependent from
non-specific systemic effects involving general metabolism,
vasculogenesis etc., produced by other proliferative stimuli such
as physical exercise (van Praag et al., 1999; Kempermann,
2008; Falone et al., 2012). We chose fluoxetine also because
it is endowed with the abilities to accelerate the maturation
of immature DCX+ cells (Wang et al., 2008) as well as to
promote the survival of progenitor cells of the dentate gyrus
(Encinas et al., 2006). Specific protocols were adopted in order
to highligth not only proliferation, but also differentiation and
survival.
We also sought to rescue the terminal differentiation defect
by physiologically inducing the maturation of dentate gyrus
neurons through a cognitive stimulus, by a specific paradigm
of spatial learning acting on 1-week-old neurons, i.e., at the
end of the proliferative phase, when the neurogenic effect of
the task is more pronounced (Gould et al., 1999; Epp et al.,
2013).
Finally, we attempted with a focused approach to genetically
complement the defective terminal differentiation, i.e., by
regulating the expression of two genes, one of which, the key
inhibitor of proneural basic helix-loop-helix (bHLH) genes,
Id3 (Lyden et al., 1999; Yokota, 2001), is strictly involved
in the Tis21-dependent mechanisms, whereas the other, the
proneural gene NeuroD2 (Schwab et al., 2000; Olson et al.,
2001), is coexpressed with Tis21 in differentiating dentate gyrus
cells.
In fact, we silenced in vivo Id3, which is negatively regulated
by Tis21 in dentate gyrus cells (Farioli-Vecchioli et al., 2009), or
we overexpressed NeuroD2.
Notably, stage 5 neurons express mainly NeuroD1, which has
been implicated in the process of hippocampal determination
and terminal differentiation (Liu et al., 2000; Schwab et al., 2000;
Gao et al., 2009), while stage 6 mature neurons co-express with
Tis21 and NeuN also NeuroD2 (Roybon et al., 2009; Attardo
et al., 2010). This latter has been shown to induce the neural
phenotype and to be involved in dentate gyrus development
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but not, so far, in the process of its terminal differentiation
(Olson et al., 2001; Sugimoto et al., 2009; Ravanpay et al.,
2010).
We show in this report that the defect of terminal
differentiation of Tis21-null dentate gyrus neurons can be
rescued genetically, either by NeuroD2 overexpression or
Id3 silencing in vivo, but not by neurogenic stimuli actingmainly,
though not exclusively, on proliferation, even accelerating the
cell cycle. This suggests that the proliferative state may influence
the amplification of progenitor cells but not their terminal
differentiation rate.
MATERIALS AND METHODS
Mouse Lines and Genotyping
The Tis21 knockout mice were of the C57BL/6 (B6) strain
and had a replacement of the entire exon II of the Tis21 gene.
Mutant mice had been generated previously, as described (Park
et al., 2004). Genotyping of mice was routinely performed
by polymerase chain reaction (PCR), using genomic DNA
from tail tips, as described (Farioli-Vecchioli et al., 2009).
Mice were maintained under standard specific-pathogen-
free conditions; all animal procedures were carried out
on male mice and completed in accordance with the
Istituto Superiore di Sanita’ (Italian Ministry of Health;
authorizations DM 442-2016-PR and DM 04/2013) and
current European (directive 2010/63/EU) Ethical Committee
guidelines.
BrdU and Fluoxetine Treatment of Mice
and Sample Preparation for
Immunohistochemistry
Differentiated (28-day-old) neurons in the dentate gyrus were
detected in Tis21 wild-type and knockout mice after treatment
with five daily i.p. injections of bromodeoxyuridine (BrdU;
95 mg/kg b.wt., 10 µl/g b.wt.; Sigma–Aldrich, S.Louis, MO,
USA) from P60 to P64, followed by perfusion at P88. In
Morris water maze (MWM) experiments BrdU was administered
at P60 (two daily injections, 95 mg/kg i.p) and analysis was
performed 21 days later. Fluoxetine (10 mg/Kg b.wt., 10 µl/g
b.wt.; Tocris Bioscience, Bristol, United Kingdom) or vehicle in
control groups (sterilized water) was administered daily by i.p.
injection to 2-month-old mice for 18 days (in proliferation and
differentiation experiments) or, in experiments aimed tomeasure
the Ts length, to 39-day-old mice for 21 days. Treatments are
summarized in Supplementary Table S1. Brains were collected
after transcardiac perfusion with 4% paraformaldehyde (PFA)
in PBS—DEPC and kept overnight in PFA. Brains of 14-day-
old mice were directly fixed by immersion in PFA. Afterwards,
brains were equilibrated in sucrose 30% and cryopreserved
at−80◦C.
Immunohistochemistry
Immunohistochemistry was performed on serial free-
floating coronal sections cut at 40 µm thickness in a
cryostat at −25◦C from brains embedded in Tissue-Tek
OCT (Sakura, Torrence, CA, USA). The sections were then
processed immunohistochemically for multiple labeling
with BrdU and other cellular markers using fluorescent
methods.
Proliferating subpopulations of progenitor cells were
identified using a goat polyclonal antibody against DCX (Santa
Cruz Biotechnology, Santa Cruz, CA, USA; SC-8066; 1:300) and
a mouse monoclonal against nestin (Millipore, Temecula, CA,
USA; MAB353; 1:100).
BrdU incorporation was visualized by denaturing DNA
through pretreatment of sections with 2N HCl 45 min at 37◦C,
followed by 0.1 M sodium borate buffer pH 8.5 for 10 min.
The sections were then incubated overnight at 4◦C with a rat
monoclonal antibody against BrdU (AbD Serotech, Raleigh,
NC, USA; MCA2060; 1:400), together with other primary
antibodies, as indicated: rabbit polyclonal antibody against
Calretinin (Swant, Bellinzona, Switzerland; 7699/4, 1:200),
mouse monoclonal antibody raised against NeuN (Millipore,
Temecula, CA, USA; MAB377; 1:300).
Proliferating, immature and terminally differentiated neurons
infected with retroviruses were visualized by means of chicken
polyclonal antibody against GFP (green fluorescent protein;
Aves Labs, Tigard, OR, USA; GFP-1010; 1:100) together with
either a rabbit monoclonal antibody against Ki67 (Thermo
Scientific, Fremont, CA, USA; SP6; 1:150), or a rabbit polyclonal
antibody against Calretinin (Swant, Bellinzona, Switzerland;
7699/4, 1:200) and a mouse monoclonal antibody raised against
NeuN (Millipore, Temecula, CA, USA; MAB377; 1:300). The
NeuroD1 antibody used in cell cycle studies was a goat
polyclonal (R&D Systems, Minneapolis, MN, USA; AF2746;
1:200).
Secondary antibodies used to visualize the antigen were
all, with the exception of the secondary anti-GFP, from
Jackson ImmunoResearch (West Grove, PA, USA) as follows: a
donkey anti-rat antiserum conjugated to tetramethylrhodamine
isothiocyanate (TRITC) (BrdU), a donkey anti-rabbit antiserum
conjugated to Cy2 (calretinin), a donkey anti-mouse antiserum
conjugated to Alexa-647 (NeuN), a donkey anti-rabbit
antiserum Cy3-conjugated (Ki67 and calretinin), a donkey
anti-mouse Cy2-conjugated (nestin) and a donkey anti-goat
Alexa 647-conjugated (DCX or NeuroD1). The secondary
antibody to visualize GFP was an anti-chicken antiserum
fluorescein-conjugated (Aves Labs). Nuclei were counterstained
by Hoechst 33258 (Sigma–Aldrich; 1 µg/ml in PBS).
Supplementary Table S1 summarizes the cell staining used
in the different experiments.
Images of the immunostained sections were obtained by laser
scanning confocal microscopy using a TCS SP5 microscope
(Leica Microsystem) equipped with Laser Diode 405, Ar
488, HeNe 543, HeNe 633. Analyses were performed in
sequential scanning mode to rule out cross-bleeding between
channels and using combinations of three different lasers
simultaneously.
Thymidine Analog Detection
For BrdU detection, see ‘‘Immunohistochemistry’’ Section above.
Concerning IdU and CldU immunohistochemistry, sections
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were washed five times in TBS (Tris-buffered saline), pretreated
with 2N HCl for 10 min, then washed five times in TBS.
Antibodies were incubated in TBS containing 5% normal
donkey serum and 0.25% Triton X-100 (Vega and Peterson,
2005).
Halogenated thymidine analogs were detected as follows: for
IdU using the mouse monoclonal anti-BrdU (BD Biosciences,
San Jose, CA, USA; BD 44; 1:500); for CldU using the rat
monoclonal anti-BrdU (AbD Serotec, Raleigh, NC, USA;
MCA2060; 1:250). Antibody specificity was analyzed in
mice that were injected with either IdU or CldU alone.
Secondary antibodies used to visualize the antigens were
a donkey anti-rat antiserum conjugated to TRITC (CldU)
and a donkey anti-mouse antiserum conjugated to Cy2
(IdU), all from Jackson ImmunoResearch (West Grove, PA,
USA).
Cell Cycle Analysis
S-phase length, measured in hours (Ts), was obtained
employing the equation developed by others (Vega
and Peterson, 2005; Brandt et al., 2012). In order to
measure Ts in 2-month-old and 2-week-old mice, we
administrated IdU intraperitoneally (57.5 mg/kg in 0.02 N
NaOH, 0.9% NaCl saline solution; MP Biomedicals,
Solon, OH, USA), and 3 h later CldU (42.5 mg/kg
b.wt. in 0.9% NaCl saline solution; Sigma–Aldrich). The
injected volumes were adjusted to the body weight. Forty-
five minutes after CldU, injected animals were killed
for immunohistochemistry. The Ts of the NeuroD1+
progenitors was obtained through triple immunofluorescence
(NeuroD1+IdU+CldU+).
Quantification of Cell Numbers
Stereological analysis of the number of cells was performed
on one-in-eight series of 40-µm free-floating coronal sections
(320 µm apart), which were analyzed by confocal microscopy
to count cells expressing the indicated marker throughout
the whole rostrocaudal extent of the dentate gyrus. To
obtain the total estimated number of cells within the dentate
gyrus, positive for each of the indicated markers, the average
number of positive cells per section was multiplied by
the total number of 40-µm sections comprising the entire
dentate gyrus (about 50–60 sections), as described (Gould
et al., 1999; Jessberger et al., 2005; Kee et al., 2007; Farioli-
Vecchioli et al., 2008, 2012). Thus, about seven sections per
mouse and at least three animals per group were analyzed.
Confocal single plane images and Z-stacks with orthogonal
projections of the immunostained sections were obtained
using a TCS SP5 confocal laser scanning microscope (Leica
Microsystems).
In Figures 3D, 4D (fluoxetine and MWM experiments,
respectively) cell numbers were calculated as ratios of stage
5 or stage 6 neurons to the total number of BrdU+ cells. The
virus-infected cells (Figures 5–7) were calculated as percentage
ratios between GFP+Ki67+ or GFP+Calretinin±NeuN+ cells
and the total number of infected cells (GFP+) in each
section, and then averaged. In each virus-injected mouse
were analyzed at least 15 sections throughout the whole
extent of the dentate gyrus; the minimum number of GFP+
cells identified per mouse was 12. Cell number analyses
were performed manually by trained experimenters using the
I.A.S. software to record positive cells (Delta Sistemi, Rome,
Italy).
Generation of Recombinant Viruses and
Infection In Vivo
The retroviral vector pCAG-IRES-GFP, kindly provided
by Dr. Chichung Lie (Institute of Developmental Genetics,
Germany; Jessberger et al., 2008), was used to express only
in dividing neural cells the cDNA of Tis21 (i.e., the murine
sequence) and NeuroD2, as well as the shId3-190 RNA
interfering sequence. The construct pCAG-IRES-GFP-Tis21 had
been generated as previously described (Farioli-Vecchioli
et al., 2014a). The construct pCAG-IRES-GFP-shId3 was
generated by cloning in the SfiI-5′/PmeI-3′ sites of pCAG-
IRES-GFP the whole 64-mer containing the 19-nucleotide
siRNA from the pSUPER.retro-neo-GFP-shId3-190 vector,
preceded by the H1 promoter and the TATA box sequence
driving the transcription. pSUPER.retro-neo-GFP-shId3-
190 was previously generated by us and the 19-nucleotide
siRNA sequence specific to mouse Id3 was shown to
efficiently reduce the Id3 mRNA levels (Farioli-Vecchioli
et al., 2014a).
The same procedure was used to obtain the pCAG-
IRES-GFP-shLUC retroviral vector, containing an sh-LUC
control sequence specifically targeting the luciferase gene
(Farioli-Vecchioli et al., 2014a). The pCAG-IRES-GFP-
NeuroD2 sequence was obtained by cloning the full open reading
frame of NeuroD2 mouse cDNA in the sites SfiI-5′/PmeI-3′ of
pCAG-IRES-GFP. The shId3, shLUC and NeuroD2 sequences
cloned into pCAG-IRES-GFP vector had been synthesized
by MWG (Ebersberg, Germany) and were checked by DNA
sequencing.
The different retroviruses, including pCAG-IRES-GFP-
shLUC, were propagated as previously described (Farioli-
Vecchioli et al., 2008). The concentrated virus solution
(108 pfu/ml) was infused (1.5 µl at 0.32 µl/min) by stereotaxic
surgery into the right and left dentate gyrus of anesthetized
P60 Tis21-null mice (anteroposterior = −2 mm from bregma;
lateral = ±1.5 mm; ventral = 2.0 mm). Infected, GFP-positive
cells were counted throughout the whole extent of the dentate
gyrus.
All the retroviruses generated were amphotropic and
replication-deficient. Their manipulation and stereotactic
injection in mice were approved by the Italian Ministry of
Health (authorizations RM/IC/Op2/06/008 and 04/2007) and
performed using BSL-2 and ABSL-2 containments.
Morris Water Maze
For the training in the MWM, the same protocol as in Farioli-
Vecchioli et al. (2009) was used, with minor modifications.
The training was carried out in a circular swimming pool of
1.3 m in diameter, filled with opaque (white) water kept at
constant temperature (25 ± 1◦C). The apparatus was located
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in a room containing prominent extra-maze cues. A hidden
15-cm-diameter platform was used. We measured the time
employed by the mouse to reach the hidden platform (s). The
training consisted of 28 trials (four trials per day, lasting a
maximum of 60 s, with an inter-trial interval of 30 min),
with the platform maintained in the same position. Mice were
left for 15 s upon the platform at the end of each trial. In
the event a mouse did not reach the platform within 60 s,
it was gently directed to the platform by the experimenter
and left for 15 s upon it (this occurred only sporadically on
the first day). No probe test was performed. Only male mice
(2 months of age; at least five per group) were used for the
experiment. Mice behavior was recorded and analyzed offline
by the EthoVision software (Noldus Information Technology,
Wageningen, Netherlands).
Statistical Analysis and Experimental
Design
Two-way ANOVA was used to compare the effects in all
experiments on wild-type and knockout mice of fluoxetine
treatment (including cell cycle length) and of MWM training;
individual between-group comparisons, where appropriate,
were carried out by Fisher’s PLSD ANOVA post hoc test.
The variance of data in the fluoxetine and MWM experiment
that were calculated as ratio of differentiated neurons (stage
5 or stage 6) to the total number of bromodeoxyuridine+
(BrdU+) cells (Figures 3D, 4D), were instead analyzed with
the Kruskall-Wallis test, which accounts for the assumption
of non-normal distribution; individual between-group
comparisons where then performed with the non parametric
Mann-Whitney U test which does not require the assumption
of normal distribution. Each experimental group analyzed
was composed of at least three animals. Mann-Whitney U
test was also used to analyze the percent values of retrovirally
infected dentate gyrus cells, as the distribution of percent
data may not comply with the assumption of a normal
distribution. These analyses were performed using the StatView
5.0 software (SAS Institute, Cary, NC, USA). Supplementary
Table S1 summarizes mice number, experimental design and
statistical tests used for each experiment. Supplementary
Table S2 summarizes two-way ANOVA and post hoc
analyses.
Differences were considered statistically significant at
p< 0.05. All data were expressed as mean values± SEM.
RESULTS
We have previously demonstrated that ablation of Tis21 causes
a selective impairment of terminal differentiation of stage 5 into
stage 6 dentate gyrus neurons (Farioli-Vecchioli et al., 2009).
We sought to ascertain whether the genetic impairment
of terminal differentiation could be rescued, at first by
enhancing the proliferation of stem/progenitor cells, and
hence the neurogenesis, by means of a pharmacological
treatment—i.e., fluoxetine, which stimulates the serotonin
pathway (Malberg et al., 2000)—or by a cognitive stimulus, the
MWM (Epp et al., 2013). Alternatively, we analyzed the effect of
genetic stimuli on differentiation.
Fluoxetine Increases the Number of
Dentate Gyrus Progenitor Cells in
Wild-Type and Tis21 Knockout Mice
As a first step, we checked in our system the known ability
of fluoxetine to induce the proliferation of progenitor cells of
the dentate gyrus (Encinas et al., 2006; Crowther and Song,
2014; Bolijn and Lucassen, 2015). We treated 2-month-old
mice with fluoxetine daily for 18 days, and then we analyzed
the ongoing proliferation of dentate gyrus cells. We observed
that the treatment with fluoxetine significantly increased the
total number of proliferating stem and progenitor cells in
the dentate gyrus (detected as Ki67+) in wild-type as well
as in mutant mice, relative to the respective control-treated
(with water) mice (Tis21WT vs. Tis21WT + FLX, 82% increase,
p < 0.0001 PLSD test; Tis21KO vs. Tis21KO + FLX, 40%
increase, p = 0.0003 PLSD test; two-way ANOVA, fluoxetine
treatment effect F(1,143) = 31.8, p < 0.0001; Figures 1A–C).
Moreover, as expected, the knockout of Tis21 in itself led to
increased proliferation of the total proliferating cells (Tis21WT
vs. Tis21KO, 55% increase, p = 0.005; Figures 1A,C). We further
checked the increase of proliferation in the subpopulations
of stem/progenitor cells. Type-1-2a cells were identified as
nestin+DCX−, type-2b progenitor cells as nestin+ and DCX+,
while type-3 cells as DCX+and nestin− (Filippov et al., 2003;
Kronenberg et al., 2003; Kempermann et al., 2004). We observed
that in wild-type as well as in mutant mice the number of
proliferating type-2b and type-3 progenitor cells was increased
by fluoxetine treatment (type-2b, Ki67+/nestin+/DCX+ cells:
Tis21WT vs. Tis21WT + FLX, 55% increase, p = 0.007;
Tis21KO vs. Tis21KO + FLX, 37% increase, p = 0.016 PLSD
test, two-way ANOVA, treatment effect F(1,143) = 13.2,
p = 0.0004; type-3, Ki67+/nestin−/DCX+ cells: Tis21WT vs.
Tis21WT + FLX, 73% increase, p = 0.013 PLSD test; Tis21KO
vs. Tis21KO + FLX, 43% increase, p = 0.002 PLSD test,
two-way ANOVA, treatment effect F(1,143) = 15.6, p = 0.0001;
Figures 1A,D).
Fluoxetine Shortens the S-Phase Length in
Tis21 Knockout Dentate Gyrus Progenitor
Cells
Then, we analyzed whether fluoxetine was in itself able to
enhance the proliferation of progenitor cells of the dentate
gyrus by modifying the length of the cell cycle. For this,
we calculated the S phase length (Ts)—which is the main
determinant of cell cycle duration—using a new accurate
procedure (Brandt et al., 2012; Farioli-Vecchioli et al., 2014b;
Figures 2A–D). We treated 39-day-old mice with fluoxetine
daily for 21 days; this protocol was used in order to
maximize the proliferative effects of fluoxetine. It turned out
that fluoxetine treatment was unable to alter the Ts of the
wild-type proliferating progenitor cells in 2-month-old mice,
whereas Ts was significantly shortened in Tis21 knockout
mice treated with fluoxetine, relative to either Tis21 knockout
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FIGURE 1 | Treatment with fluoxetine significantly increases the number of dentate gyrus progenitor cells in adult (2-month-old) wild-type and Tis21 knockout mice.
(A) Representative confocal images (20× magnification) showing proliferating dentate gyrus progenitor cells, labeled by Ki67 (red), in mice treated as described in
(B). Their number increases in Tis21KO mice, as compared to Tis21WT mice, and is increased also by fluoxetine in both the Tis21KO and Tis21WT genotypes, relative
to the corresponding water-treated controls. The dotted lines define the outer boundary of the granule cell layer. Scale bar, 100 µm. (B) Scheme of the protocol
followed: 2-month-old mice were treated daily with fluoxetine for 18 days and then analyzed. (C) Quantification of total proliferating adult progenitor cells in wild-type
and Tis21 knockout dentate gyrus, measured as Ki67-positive cells; both were significantly increased by fluoxetine. Moreover, the ablation of Tis21 induced in itself
an increase of total proliferating cells, relative to wild-type. Simple effects analysis: ∗∗p < 0.01, or ∗∗∗p < 0.001; PLSD ANOVA test. (D) Quantification of individual
proliferating stem and progenitor cell subpopulations in wild-type and Tis21KO dentate gyrus, measured as Ki67-positive cells. The number of type-2b and type-3
progenitor cells is significantly induced by fluoxetine in both Tis21WT and Tis21KO mice. Simple effects analysis: ∗p < 0.05, ∗∗p < 0.01, or NS p > 0.05, PLSD
ANOVA test. (C,D) Cell numbers in the dentate gyrus are mean ± SEM of the analysis of 4–6 animals per group (see Supplementary Table S1).
mice control-treated or wild-type control-treated (Tis21KO vs.
Tis21KO + FLX, p = 0.02 PLSD test, two-way ANOVA,
treatment effect F(1,164) = 2.04, p = 0.15; Tis21WT vs. Tis21KO
+ FLX, p = 0.033 PLSD test; Figures 2A–C). We also checked
whether fluoxetine affected the Ts of the subpopulation of
progenitor cells at the threshold of differentiation, i.e., the
type-3 neuroblasts, which express NeuroD1 (Roybon et al.,
2009). These cells in fact, since they are at a pre-differentiation
stage, may represent an interesting target for our analysis.
However, no significant change of Ts induced by fluoxetine
was observed in NeuroD1+ cells (two-way ANOVA, treatment
effect F(1,102) = 1.10, p = 0.29; Figure 2D). Moreover, the
ablation of Tis21 in itself did not alter Ts in 2-month-
old dentate gyrus progenitor cells, relative to wild-type mice
(Figures 2C,D). However, considering that Tis21, in addition
to the intrinsic pro-differentiative function, has antiproliferative
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FIGURE 2 | Treatment with fluoxetine significantly reduces the length of the S phase in Tis21 knockout 2-month-old dentate gyrus progenitor cells.
(A) Representative confocal images of cycling cells (40× magnification), with 3D reconstruction from Z-stack and orthogonal projections of triple- and
double-positive cells. Cycling cells are shown: (i) cells in S-phase during the 3 h interval after the IdU pulse and before CldU (IdU+/CldU− cells, green, arrow; or
NeuroD1+/IdU+/CldU−, blue-green, arrows with dotted line); (ii) cells in S-phase during the CldU pulse (IdU−/CldU+cells, red, arrowhead); (iii) or cells that were in
S-phase during both pulses and continued throughout the cell cycle (IdU+/CldU+, yellow-green, asterisk; or NeuroD1+/IdU+/CldU+, white, at lines intersection).
Scale bar, 50 µm. (B) Treatment timeline: 2-month-old wild-type and Tis21 knockout mice, after fluoxetine treatment for 21 days, were injected with IdU and CldU
3 h and 45 min, respectively, before analysis. (B′) Equation to calculate the S-phase length. The ratio of cells that have left the S phase during the interval of 3 h
between injections (IdU+/CldU− cells) to the total number of IdU+ cells is equal to 3 h/Ts. (C) Graphs showing the measurement of the length of the S phase (Ts) for
the total population of progenitor cells and (D) for the NeuroD1+ progenitor cells population in the different experimental conditions. (C) A shortening of Ts is evident
only in the total population of progenitor cells, in the Tis21KO + FLX mice with respect to the Tis21WT and Tis21KO mice. Analysis of simple effects: ∗p < 0.05, PLSD
ANOVA test. (D) NeuroD1+ progenitor cell population, analysis of simple effects: NS p > 0.05, PLSD ANOVA test. Data are mean ± SEM of the analysis of five (C) or
3–4 (D) animals per group (see Supplementary Table S1). (E) Treatment timeline and (F) analysis of S phase length (Ts) for the total proliferating stem/progenitor cells
or (G) for the NeuroD1+ progenitor cells in 2-week-old wild-type and Tis21 knockout mice. ∗p < 0.05, or ∗∗∗p < 0.001 Student’s t test. Data are mean ± SEM of the
analysis of three animals per group.
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properties (Farioli-Vecchioli et al., 2009), it seemed appropriate
to test whether the deletion of Tis21 could in itself modify
the cell cycle length at an earlier age —2 weeks— when the
proliferation in the dentate gyrus is stronger (Gilley et al.,
2011). We found that indeed the Ts of the total population
of stem/progenitor cells in 14-day-old Tis21 knockout mice
resulted significantly shorter than in wild-type mice (about 19%
decrease, p = 0.0005; Figures 2E,F). Furthermore, a significant
decrease was observed also for the Ts of the subpopulation
of NeuroD1+ progenitor cells (21% decrease, p = 0.023;
Figures 2E,G).
Taken together, these data indicated that: (i) fluoxetine
enhances the proliferation of the adult wild-type dentate gyrus
progenitor cells, but is able to accelerate the S phase only
in mice ablated of Tis21 (probably because of a permissive
condition consequent to the absence of the antiproliferative
Tis21); and that (ii) the knockout of Tis21 in itself causes an
acceleration of the S phase although detectable only in young
mice.
Fluoxetine Enhances the Generation of
Early and Late Differentiated Neurons in
the Dentate Gyrus, but Does Not Rescue
the Defective Terminal Differentiation of
Tis21 Knockout Neurons
Having ascertained that fluoxetine exerts a powerful proliferative
effect in mice of about 2-months of age on Tis21 knockout and
wild-type dentate gyrus progenitor cells, we studied the effect of
fluoxetine treatment on their terminal differentiation.
P60 mice were treated with fluoxetine for 18 days and
injected with BrdU daily for the last 5 days of fluoxetine
treatment. Dentate gyrus cells were analzyed at the end of the
treatment, in this way monitoring essentially the proliferative
effect of fluoxetine on progenitor cells. We observed that,
although fluoxetine induced in both wild-type and knockout
mice an increase of the number of immature and terminally
differentiated neurons, fluoxetine was not able to restore their
rate of differentiation (measured over the total number of BrdU+
cells) in mutant mice (data not shown and Supplementary
Table S1).
Thus, we modified the protocol of treatment by adding
at the end an off treatment period of 10 days, in order to
allow the differentiation of the newly generated progenitor
cells, and to better assess whether fluoxetine is able to
accelerate the differentiation of progenitor cells in mutant mice
(Supplementary Figures S1A–C).
We observed that fluoxetine significantly increased in
both wild-type and knockout mice the number of stage 5
(BrdU+/Calretinin+/NeuN+, hereafter named as BrdU+/stage 5,
Tis21WT vs. Tis21WT + FLX, p = 0.02 PLSD test; Tis21KO
vs. Tis21KO + FLX, p = 0.009 PLSD test, two-way ANOVA,
treatment effect F(1,121) = 11.74, p = 0.0008; Supplementary
Figure S1C) and stage 6 neurons (BrdU+/Calretinin−/NeuN+,
hereafter named as BrdU+/stage 6, Tis21WT vs. Tis21WT
+ FLX, p = 0.008 PLSD test; Tis21KO vs. Tis21KO +
FLX, p = 0.005 PLSD test, two-way ANOVA, treatment
effect F(1,121) = 15.23, p = 0.0002; Supplementary Figure
S1C).
Notably, while the rate of differentiation after fluoxetine,
measured as the ratio of terminally differentiated neurons to
the total number of BrdU+ 10- to 15-day-old neurons, was
restored to normal values in stage 5 neurons, the rate of
stage 6 neurons remained lower in mutant mice relative to
wild-type, indicating that no rescue of the defect of terminal
differentiation occurred (BrdU+/stage 6 in total BrdU+: Tis21WT
+ FLX vs. Tis21KO + FLX, p < 0.0001, Mann-Whitney U test,
Kruskall-Wallis (d.f. 3) H = 45.42, p < 0.0001; Supplementary
Figure S1D).
Next, we decided to modify the protocol by anticipating
BrdU injections at the beginning of the treatment, in order
to detect the initial amplification of the different cohorts
of neurons throughout the process of maturation during
the treatment with fluoxetine, which is also endowed with
a prodifferentiative action (Wang et al., 2008). We left the
off treatment period of 10 days at the end, to allow the
complete differentiation of the newly generated progenitor
cells. Such protocol would highlight the effect of fluoxetine
treatment not only on the proliferation and differentiation
but also on the survival of progenitor cells (Encinas et al.,
2006).
As a preliminary test, we checked whether the new conditions,
with five daily injections of BrdU from the first day of
treatment, allow to detect the proliferative effect of fluoxetine
(Supplementary Figures S2A–C). In fact, a previous study
indicated that an increase of BrdU+ cells by fluoxetine was
detected between 5 days and 14 days of treatment, after, however,
a single injection of BrdU before treatment (Malberg et al., 2000).
We observed that BrdU+ cells are significantly increased by
fluoxetine treatment for 7 days (BrdU+, Tis21WT vs. Tis21WT +
FLX, one-way ANOVA F(1,70) = 4.6, p = 0.035; Supplementary
Figure S2C), plausibly before a fluoxetine-dependent survival
action may take place (Caiaffo et al., 2016). Therefore, our
protocol appears to be suited to detect the effect of fluoxetine
on both proliferation and differentiation of progenitor cells, with
also a prosurvival component that certainly plays a part during
the treatment.
Thus, we induced the process of neurogenesis by treating
P60 mice with fluoxetine for 18 days, followed by a period of
10 days in the absence of treatment, to allow the differentiation
of the newly generated progenitor cells. New neurons were
labeled by five daily injections of BrdU performed during
the first 5 days of fluoxetine treatment (Figures 3A,B; see
scheme 3B). This protocol, from Wang et al. (2008) with
modifications, allows detection of new 23- to 28-day-old
differentiated neurons, generated with or without the neurogenic
stimulus of fluoxetine.
We observed an increase of immature stage 5 neurons
in Tis21 knockout mice, relative to wild-type (BrdU+/stage
5 neurons, p = 0.028 PLSD test; Figures 3A,C) and a decrease
of terminally differentiated stage 6 neurons (BrdU+/stage
6 neurons, p = 0.03; Figures 3A,C), as expected. Fluoxetine
significantly increased in wild-type and in mutant mice
the number of differentiated neurons, either immature
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(BrdU+/stage 5, Tis21WT vs. Tis21WT + FLX, p = 0.007 PLSD
test; Tis21KO vs. Tis21KO + FLX, p = 0.0013 PLSD test,
two-way ANOVA, treatment effect F(1,80) = 18, 466, p < 0.0001;
Figure 3C), or terminally differentiated (BrdU+/stage 6, Tis21WT
vs. Tis21WT + FLX, p < 0.0001 PLSD test; Tis21KO vs. Tis21KO
+ FLX, p = 0.0004 PLSD test, two-way ANOVA, treatment
effect F(1,79) = 72.355, p < 0.0001; Figure 3C). The increase of
28-day-old neurons confirms that the cell cycle acceleration of
progenitor cells induced by fluoxetine enhances the generation
of viable neurons. Fluoxetine treatment, however, was unable
to functionally counteract the impairment of differentiation
occurring in Tis21 knockout mice, as the number of terminally
differentiated neurons (BrdU+/stage 6) observed in mutant mice
after fluoxetine treatment remained significantly lower than
in wild-type mice treated with fluoxetine (Tis21KO + FLX vs.
Tis21WT + FLX, p< 0.0001 PLSD test; Figure 3C).
Moreover, if we visualize in Figure 3D the rate of
differentiation by analyzing the ratio of terminally differentiated
neurons (BrdU+/stage 6) to the total number of BrdU+ 23- to
28-day-old neurons, this was slightly but significantly changed
by fluoxetine in wild-type, indicating a mild pro-differentiative
effect by fluoxetine. However, again, no change by fluoxetine
occurred in the ratio of immature or terminally differentiated
neurons of mutant mice (BrdU+/stage 5 in total BrdU+: Tis21WT
vs. Tis21WT + FLX, p = 0.14 or Tis21KO vs. Tis21KO + FLX,
p = 0.09Mann-Whitney U test, Kruskall-Wallis (d.f. 3)H = 38.92,
p < 0.0001; BrdU+/stage 6 in total BrdU+: Tis21WT vs. Tis21WT
+ FLX, p = 0.017 or Tis21KO vs. Tis21KO + FLX, p = 0.30
Mann-Whitney U test, Kruskall-Wallis (d.f. 3) H = 30.96,
p < 0.0001; Figure 3D). In fact, the pattern of increase of
stage 5 neurons and the decrease of stage 6 neurons elicited
by Tis21 knockout, relative to wild-type mice, remained the
same also after fluoxetine treatment (BrdU+/stage 5 in total
BrdU+: Tis21WT + FLX vs. Tis21KO + FLX, p < 0.0001,
Mann-Whitney U test; BrdU+/stage 6 in total BrdU+: Tis21WT
+ FLX vs. Tis21KO + FLX, p < 0.0001, Mann-Whitney U test;
Figure 3D).
As a whole, this indicates that the defect of terminal
differentiation of stage 5 into stage 6 neurons in Tis21 knockout
mice is refractory to rescue by the proliferative and
pro-differentiative neurogenic stimulus of fluoxetine, and
suggests that this process is separate from the expansion of
progenitor cells.
Training in the Morris Water Maze
Enhances Neurogenesis in the Dentate
Gyrus, but Fails to Rescue the Defective
Terminal Differentiation of Tis21 Knockout
Neurons
As a second step, we tested whether a different neurogenic
stimulus —namely, spatial learning in the MWM— could rescue
the differentiation defect of Tis21 knockout dentate gyrus. It
has in fact been demonstrated that spatial learning activates
neurogenesis and promotes the survival and incorporation of
new neurons into the dentate gyrus (Gould et al., 1999). The
neurogenic effect of spatial learning appears more pronounced
in 1-week-old neurons, as determined by BrdU birth-dating
(Epp et al., 2013). We decided to highlight the process of
neuron differentiation, by analyzing the new neurons generated
21 days after two daily injections of BrdU, whereas the
MWM training was performed from day 8 to day 14, when
the proliferative phase was almost concluded (Figures 4A,B,
see scheme 4B). This timeline was chosen following, with
modifications, published protocols (Dupret et al., 2007; Epp
et al., 2007). The experiments were performed in 2-month-old
mice.
The MWM was performed as described in Farioli-Vecchioli
et al. (2009) with minor modifications. In this task, mice
learn across daily sessions to find a hidden escape platform
using extra-maze visual cues. Tis21KO and Tis21WT mice
performed equally in the task (Supplementary Figure S3).
MWM training elicited in the dentate gyrus of both wild-type and
Tis21 knockout mice a significant increase of immature neurons
(BrdU+/stage 5, Tis21WT vs. Tis21WT + MWM, p = 0.042;
Tis21KO vs. Tis21KO + MWM, p < 0.0001 PLSD test, two-way
ANOVA, MWM effect F(1,270) = 27.17, p < 0.0001; Figure 4C),
as well as of terminally differentiated neurons (BrdU+/stage 6,
Tis21WT vs. Tis21WT + MWM, p < 0.002 PLSD test; Tis21KO
vs. Tis21KO + MWM, p = 0.011 PLSD test, two-way ANOVA,
MWM effect F(1,270) = 15.35, p = 0.0001; Figure 4C). Notably,
after MWM training the difference between the number of
wild-type and Tis21 knockout terminally differentiated neurons
was reduced to a non-significant level, suggesting that some
rescue of terminal differentiation occurred (BrdU+/stage 6,
Tis21WT + MWM vs. Tis21KO + MWM, p = 0.070 PLSD
test; Figure 4C). Nevertheless, when we analyzed the ratio of
stage 5 or 6 neurons to the total number of BrdU+ neurons,
no change was exerted by MWM training (BrdU+/stage 5 in
total BrdU+: Tis21WT vs. Tis21WT + MWM, p = 0.87 or
Tis21KO vs. Tis21KO + MWM, p = 0.37 Mann-Whitney U test,
Kruskall-Wallis (d.f. 3) H = 30.41, p < 0.0001; BrdU+/stage 6 in
total BrdU+: Tis21WT vs. Tis21WT + MWM, p = 0.68 or Tis21KO
vs. Tis21KO + MWM, p = 0.57 Mann-Whitney U test, Kruskall-
Wallis (d.f. 3) H = 36.17, p < 0.0001; Figure 4D). Hence, the
Tis21 knockout-induced pattern of increase of stage 5 neurons
and decrease of stage 6 neurons, relative to wild-type mice,
remained the same also after MWM training, indicating that
the defect in the differentiation rate of Tis21 knockout neurons
was not rescued (BrdU+/stage 5 in total BrdU+: Tis21WT +
MWM vs. Tis21KO + MWM, p < 0.0001, Mann-Whitney
U test; BrdU+/stage 6 in total BrdU+: Tis21WT + MWM
vs. Tis21KO + MWM, p < 0.0001, Mann-Whitney U test;
Figure 4D).
The Impairment of Differentiation in
Tis21-Null Progenitor Cells of the Dentate
Gyrus Is Rescued by Id3 Silencing and by
NeuroD2
As a way to assess the specificity of impairment of the
differentiation observed in Tis21 knockout mice, we sought to
rescue it by injecting in the dentate gyrus retroviruses expressing
(or silencing) either Tis21 (Figure 5) or genes regulating neural
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FIGURE 3 | Treatment with fluoxetine highly increases the generation of early and late differentiated neurons in the adult dentate gyrus, but does not rescue the
impairment of terminal differentiation in Tis21 knockout neurons. (A) Representative images (40× magnification) of the dentate gyrus of wild-type and mutant mice
treated as in (B), showing early postmitotic immature neurons (stage 5, identified as bromodeoxyuridine+ (BrdU+)/Calretinin+/NeuN+ cells; white arrowheads), and
terminally differentiated neurons (stage 6 neurons, identified as BrdU+/Calretinin−/NeuN+ cells). Fluoxetine increases the absolute numbers of both stage 5 and
stage 6 neurons in wild-type as well as Tis21 knockout dentate gyrus. Scale bar, 50 µm. The white box area is shown with 1.8× digital magnification. (B) Scheme of
the protocol followed to detect new 28-day-old differentiated neurons: 2-month-old mice received five daily injection of BrdU at the beginning of the fluoxetine
treatment, which was discontinued at day 18 for the following 10 days before analysis. (C) Quantification of the number of new 28-day-old cells indicates an increase
in Tis21-null dentate gyrus of stage 5 immature neurons (BrdU+/Calretinin+/NeuN+) and a decrease of terminally differentiated stage 6 neurons
(BrdU+/Calretinin−/NeuN+), relative to wild-type. Fluoxetine highly increases both stage 5 and stage 6 neurons in wild-type as well as Tis21 knockout dentate gyrus.
Simple effects analysis: ∗p < 0.05, ∗∗p < 0.01, or ∗∗∗p < 0.001; PLSD ANOVA test. Cell numbers in the dentate gyrus are mean ± SEM of the analysis of three
animals per group. (D) The ratio of immature neurons (stage 5, BrdU+/Calretinin+/NeuN+) or of terminally differentiated neurons (stage 6, BrdU+/Calretinin−/NeuN+)
to the total number of BrdU+ 23- to 28-day-old neurons was unchanged by fluoxetine treatment in the different genotypes, except in stage 6 wild-type neurons.
Simple effects analysis: NS, p > 0.05, ∗p < 0.05, ∗∗∗p < 0.001; Mann-Whitney U test.
differentiation at specific steps, namely, Id3 (Figure 6) and
NeuroD2 (Figure 7). The gene Id3, which negatively regulates
neural differentiation (Lyden et al., 1999; Andres-Barquin et al.,
2000; Yokota, 2001), has been previously shown to be strongly
repressed by Tis21 in dentate gyrus neurons (Farioli-Vecchioli
et al., 2009); whereas NeuroD2 is involved in the process of
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FIGURE 4 | Spatial training in the Morris water maze (MWM) test increases the generation of early and late differentiated neurons in the adult dentate gyrus, but is
unable to rescue the defect of terminal differentiation in Tis21 knockout neurons. (A) Representative confocal images (40× magnification) of the dentate gyrus of
Tis21-null mice showing postmitotic immature neurons (stage 5, BrdU+/Calretinin+/NeuN+ cells; white arrowheads) and terminally differentiated neurons (stage 6,
BrdU+/Calretinin−/NeuN+ cells); MWM-trained mice show a higher number of stage 5 and stage 6 neurons in the wild-type and in Tis21 knockout dentate gyrus.
Scale bar, 50 µm. The white box area is shown with 1.5× digital magnification. (B) Timeline of the protocol followed to detect new 21-day-old differentiated neurons,
with two daily injection of BrdU at days 0–1, followed by 7 days of MWM training (day 8–14) and analysis at day 21. (C) MWM training highly increases the new
21-day-old immature neurons (stage 5, BrdU+/Calretinin+/NeuN+) and the stage 6 differentiated neurons (BrdU+/Calretinin−/NeuN+) in wild-type as well as in
Tis21 knockout dentate gyrus. Simple effects analysis: ∗p < 0.05, ∗∗p < 0.01, or ∗∗∗p < 0.001; PLSD ANOVA test. Cell numbers in the dentate gyrus are
mean ± SEM of the analysis of five animals per group. (D) The differentiation rate (calculated as ratio of stage 5 immature neurons or of stage 6 terminally
differentiated neurons to the total number of BrdU+ 21-day-old neurons) did not change in the different genotypes. Simple effects analysis: NS, p > 0.05,
∗∗∗p < 0.001; Mann-Whitney U test.
dentate gyrus development and survival (Olson et al., 2001)
and is amongst the bHLH genes target of the inhibitory
activity of Id3.
The infection of the dentate gyrus of Tis21-null adult
mice (at P60) with a retrovirus expressing Tis21 and GFP
(pCAG-IRES-GFP-Tis21; Figures 5A–E) occurred only in
proliferating progenitors; however, the analysis of infected
cells (GFP+) was performed 5 days after infection, hence
cells were detected that either continued to proliferate or had
differentiated. The pCAG-IRES-GFP-Tis21 virus effectively
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FIGURE 5 | Tis21-retrovirus inhibits the deregulated proliferation of dentate gyrus progenitor cells and rescues the defective terminal differentiation of Tis21-null
neurons. (A) Scheme of retrovirus infection timeline, structure, and injection area. (B) Representative confocal images (40× magnification) of coronal sections of the
dentate gyrus, labeled with Hoechst 33258, Ki67 and with GFP, 5 days after infection with either GFP-Tis21 or GFP-empty retroviruses. Scale bars, 50 µm. The
white arrowheads indicate cells positive for both GFP and Ki67, white arrows cells positive only for GFP. (C) Percentage ratio between GFP+Ki67+ cells and the total
number of infected cells (GFP+), from the analysis of Tis21 knockout dentate gyrus infected with either GFP-Tis21 or GFP-empty virus. The percentage of dividing
cells (Ki67+) is reduced by the Tis21 virus, relative to the empty virus infections. ∗p < 0.05 vs. cells infected with GFP-empty virus; Mann-Withney U test.
(D) Representative confocal images of dentate gyrus cells triple labeled with Calretinin, NeuN and GFP, 5 days after infection with either GFP-Tis21 or GFP-empty
retroviruses. Scale bars, 50 µm. White arrows indicate infected terminally differentiated neurons (GFP+Calretinin−NeuN+); arrowheads indicate infected stage
5 immature neurons (GFP+Calretinin+NeuN+). (E) Percentage ratio between stage 5 immature neurons (GFP+stage 5) or stage 6 terminally differentiated neurons
(GFP+stage 6) and the total number of infected cells (GFP+), analyzed in Tis21 knockout dentate gyrus infected with either GFP-Tis21 or GFP-empty virus. The
percentages of stage 5 and stage 6 neurons infected with empty virus are significantly decreased or increased, respectively, by the Tis21-expressing virus.
∗p < 0.05 or ∗∗∗p < 0.001 vs. cells infected with GFP-empty virus; Mann-Withney U test. (C,E) Cell ratios in the dentate gyrus are mean% ± SEM of the analysis of
three animals per group.
inhibited the proliferation of dividing progenitors (GFP-
Tis21+Ki67+/total GFP-Tis21+ vs. GFP-empty+Ki67+/total
GFP-empty+ p = 0.015, Mann Whitney U test, used hereafter
for virus infection analyses; Figures 5A,C); in parallel, the high
percentage of immature stage 5 neurons and the low percentage
of terminally differentiated stage 6 neurons present in Tis21-null
dentate gyrus was reversed (stage 5: GFP-Tis21+stage 5/total
GFP-Tis21+ vs. GFP-empty+stage 5/total GFP-empty+
p = 0.037; stage 6: GFP-Tis21+stage 6/total GFP-Tis21+ vs.
GFP-empty+stage 6/total GFP-empty+ p = 0.001; Figures 5D,E).
These data clearly indicate that the defect of differentiation of
dentate gyrus progenitor cells is specifically dependent on the
loss of Tis21.
Given that non-specific stimuli triggering the whole
neurogenic machinery, either by activation of the serotoninergic
pathway, or promoting the process of differentiation through
cognitive training, did not rescue the defect of terminal
differentiation, we now tested the specific silencing of Id3. In
fact Id3 is an inhibitor of the proneural bHLH genes (Lyden
et al., 1999; Yokota, 2001), and is negatively regulated at
transcriptional level by Tis21 in neural cells (Farioli-Vecchioli
et al., 2009).
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Thus, we infected the dentate gyrus cells of Tis21-null
mice with a retrovirus expressing GFP and an shRNA
targeting specifically Id3 (GFP-shId3), which had been
previously generated and checked for its efficiency in silencing
Id3 expression (Farioli-Vecchioli et al., 2009; Figures 6A–E). We
observed that the percentage of dividing progenitors observed
in Tis21-null mice was not affected by the infection with the
GFP-shId3 retrovirus, as compared to a control retrovirus
expressing an shRNA targeting luciferase (GFP-shLUC,
Farioli-Vecchioli et al., 2014a; GFP-shId3+Ki67+/total GFP-
shId3+ vs. GFP-shLUC+Ki67+/total GFP-shLUC+ p = 0.35;
Figures 6A,C). In contrast, the percent accumulation of
immature neurons and the lower percent ratio of terminally
differentiated neurons occurring in Tis21-null dentate gyrus
were reversed by GFP-shId3 retrovirus (stage 5: GFP-
shId3+stage 5/total GFP-shId3+ vs. GFP-shLUC+stage 5/total
GFP-shLUC+ p = 0.006; stage 6: GFP-shId3+stage 6/total
GFP-shId3+ vs. GFP-shLUC+stage 6/total GFP-shLUC+
FIGURE 6 | shId3-retrovirus rescues the defective terminal differentiation of Tis21-null neurons without effects on proliferating cells. (A) Retrovirus infection timeline,
structure and injection area. (B) Representative confocal images (40× magnification) of coronal sections of the dentate gyrus, labeled with Hoechst 33258 and with
Ki67 and GFP, 5 days after infection with either GFP-shId3 or GFP-shLUC (control) retroviruses. Scale bars, 50 µm. The white arrowheads indicate cells positive for
both GFP and Ki67. (C) Percentage ratio between GFP+Ki67+ cells and the total number of infected cells (GFP+), in Tis21 knockout dentate gyrus infected with
GFP-shId3 or GFP-shLUC virus. The ratio of dividing cells (Ki67+) is not changed by the shId3 virus, relative to the shLUC control virus infections. NS, p > 0.05 vs.
cells infected with GFP-shLUCvirus; Mann-Withney U test. (D) Representative confocal images of dentate gyrus cells triple-labeled with Calretinin, NeuN and GFP,
5 days after infection with either GFP-shId3 or GFP-shLUC retroviruses. Scale bars, 50 µm. White arrows indicate infected terminally differentiated neurons
(GFP+Calretinin−NeuN+); arrowheads indicate infected stage 5 immature neurons (GFP+Calretinin+NeuN+). (E) Percentage ratio between stage 5 immature
neurons (GFP+stage 5) or stage 6 terminally differentiated neurons (GFP+stage 6) and the total number of infected cells (GFP+), analyzed in Tis21 knockout dentate
gyrus infected with either GFP-shId3 or GFP-shLUC virus. The percentages of stage 5 neurons or stage 6 neurons observed in the shLUC virus infections are
significantly decreased or increased, respectively, by the shId3 virus. ∗p < 0.05 or ∗∗p < 0.01 vs. cells infected with GFP-shLUC virus; Mann-Withney U test.
(C,E) Cell ratios in the dentate gyrus are mean% ±SEM of the analysis of three animals per group.
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p = 0.043; Figures 6D,E). Of note, the measurement of stage
5/6-infected cells (i.e., GFP+) was performed in all infection
experiments as ratio to the total number of GFP+ cells, and is
therefore a percentage analysis analogous to that used to measure
FLX-treated progenitor cells above background in Figure 3D.
Thus, the silencing of Id3 expression specifically rescues the
Tis21 knockout-dependent defect of differentiation of dentate
gyrus progenitor cells, without effect on their proliferation.
This reveals that Id3 is a specific regulator of the terminal
differentiation of dentate gyrus progenitor cells, where it acts
under control of Tis21 (Farioli-Vecchioli et al., 2009), and that
proliferation and differentiation in this system are genetically
dissociable.
We further tested whether the proneural gene NeuroD2 could
specifically rescue the defect of terminal differentiation of
Tis21-null neurons. This choice was based on the fact that
NeuroD2 has been shown to induce neural differentiation in
embryonic stem cells (Sugimoto et al., 2009) and to be selectively
expressed in stage 6 dentate gyrus neurons, i.e., with Tis21
(Roybon et al., 2009; Attardo et al., 2010).
FIGURE 7 | NeuroD2-retrovirus rescues the defective terminal differentiation of Tis21-null neurons without affecting the proliferation of progenitor cells. (A) Retrovirus
infection timeline, structure and injection area. (B) Representative confocal images (40× magnification) of coronal sections of the dentate gyrus, labeled with Hoechst
33258, Ki67 and with GFP, 5 days after infection with either GFP-NeuroD2 or GFP-empty retroviruses. Scale bars, 50 µm. The white arrowheads indicate cells
positive for both GFP and Ki67, white arrows cells positive only for GFP. (C) Percentage ratio between GFP+Ki67+ cells and the total number of infected cells
(GFP+), in Tis21 knockout dentate gyrus infected with GFP-NeuroD2 or GFP-empty retroviruses. The percentage of dividing cells (Ki67+) is reduced, although not
significantly, by the NeuroD2 virus, relative to control virus infections. NS, p > 0.05 vs. cells infected with GFP-empty retrovirus; Mann-Withney U test.
(D) Representative confocal images of dentate gyrus cells triple-labeled with Calretinin, NeuN and GFP, 5 days after infection with either GFP-NeuroD2 or GFP-empty
retroviruses. Scale bars, 50 µm. White arrows: infected terminally differentiated neurons (GFP+Calretinin−NeuN+); arrowheads: infected stage 5 immature neurons
(GFP+Calretinin+NeuN+). (E) Percentage ratio of stage 5 immature neurons (GFP+stage 5) or stage 6 terminally differentiated neurons (GFP+stage 6) to the total
number of infected cells (GFP+), analyzed in Tis21 knockout dentate gyrus infected with either GFP-NeuroD2 or GFP-empty retrovirus. The higher percentage of
stage 5 and the lower percentage of stage 6 control-infected neurons are equalized by the NeuroD2 virus. ∗p < 0.05 or ∗∗∗p < 0.001 vs. cells infected with
GFP-empty virus; Mann-Withney U test. (C,E) Cell ratios in the dentate gyrus are mean% ± SEM of the analysis of three animals per group.
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Thus, we generated a retrovirus expressing GFP and the
NeuroD2 coding region (GFP-NeuroD2) and used it to infect
the dentate gyrus cells of Tis21-null mice. We noticed a
manifest decrease, albeit below significance, of the proliferating
stem/progenitor cells expressing the NeuroD2 virus, relative
to control-infected cells (GFP-NeuroD2+Ki67+/total GFP-
NeuroD2+ vs. GFP-empty+Ki67+/total GFP-empty+ p = 0.15;
Figures 7A,C). In contrast, the higher percentage of stage
5 immature neurons and the lower percentage of terminally
differentiated neurons occurring in Tis21-null dentate gyrus
were overturned in cells infected by the NeuroD2 retrovirus
(stage 5: GFP-NeuroD2+stage 5/total GFP-NeuroD2+ vs. GFP-
empty+stage 5/total GFP-empty+ p = 0.0004; stage 6: GFP-
NeuroD2+stage 6/total GFP-NeuroD2+ vs. GFP-empty+stage
6/total GFP-empty+ p = 0.044; Figures 7D,E). This indicates that
NeuroD2, similarly to Id3, is a specific regulator of the terminal
differentiation of dentate gyrus progenitor cells, able to rescue the
defect of differentiation in Tis21-null dentate gyrus neurons.
DISCUSSION
We have previously shown that the timing of differentiation
is crucial for the correct maturation and function of the
hippocampal neuron. In fact we have observed that the
acceleration of the process of differentiation, exerted by
conditionally overexpressing in dentate gyrus progenitor cells,
the pro-differentiative gene Tis21 activated in a transgenic
mouse, drastically impairs the functionality of the neuron
to encode and retrieve memories. Such impairment is more
pronounced than that caused by the deletion of new neurons,
and is probably consequent to the dominant negative effect
of recruiting in memory circuits a functionally defective new
neuron (Farioli-Vecchioli et al., 2008; Tirone et al., 2013).
Here we observe that in a neuron with a genetic impairment
of terminal differentiation, dependent on the ablation of Tis21,
a neurogenic stimulus triggering a very strong proliferation of
progenitor cells such as that induced by fluoxetine, although
able to accelerate the cell cycle rate of Tis21-knockout dentate
gyrus progenitor cells, is not sufficient to enhance the rate of
differentiation. Our aim was to test whether it was possible to
rescue the defect of differentiation by increasing the pool of
progenitor cells committed to differentiation, using a neurogenic
stimulus that is mainly proliferative, like fluoxetine, but at
the same time able to accelerate the maturation of immature
DCX+ cells (Wang et al., 2008) and also to promote the
survival (Encinas et al., 2006). We also considered that stage
5 cells, whose differentiation is impaired in Tis21 knockout
dentate gyrus, are immature DCX+ cells. Notably, recently
Brandt et al. (2012) showed that progenitor cells type-2b/3
(NeuroD1+) divide faster than earlier progenitor cells, suggesting
that cells committed to amplification progress faster toward
differentiation. We reasoned that a neurogenic stimulus may
trigger such activation. These concepts are compatible also with
the notion that cell cycle-dependent mechanisms modulate the
activation of differentiation genes (Dalton, 2015). The idea to test
the application of a strong external neurogenic stimulus came
also from the fact that the increase of proliferation resulting
from the deletion of Tis21 is temporally separated from the
impairment of terminal differentiation, given that Tis21 is not
expressed in stage 5 cells.
Fluoxetine increases the proliferation of progenitor cells,
probably by increasing the serotonin (5HT) available to bind
the 5HT3,4,6,7 receptors present in the hippocampus, and/or
by inhibiting p21 expression (Encinas et al., 2006; Pechnick
et al., 2011; Bolijn and Lucassen, 2015). Remarkably, despite
the strong neurogenic action, we did not uncover any effect
of fluoxetine on the length of the cycle of wild-type stem and
progenitor cells, unlike what we have observed for another
neurogenic stimulus, i.e., physical exercise (Farioli-Vecchioli
et al., 2014b). This indicates that a neurogenic stimulus can
induce neural proliferation without necessarily altering cell cycle
length. Nevertheless, a significant acceleration of the S phase
is exerted by fluoxetine in the progenitor cells lacking Tis21,
probably as a consequence of the missing control of cell cycle
normally exerted by Tis21. Notably, fluoxetine appears to be
endowed also with a mild intrinsic pro-differentiative effect
on new wild-type neurons, as in our treatment we observe an
increase of the differentiation rate (ratio of 28-day-old neurons to
the total number of new neurons generated, Figure 3D). A direct
pro-differentiative effect of fluoxetine in dentate gyrus neurons
had not been observed by Encinas et al. (2006), while it has been
reported by Wang et al. (2008), also in line with the finding that
fluoxetine increases BDNF expression in the bodies of dentate
gyrus cells, where it has a strong influence on their maturation
(Molteni et al., 2006; Waterhouse et al., 2012).
We adopted different protocols of treatment with
fluoxetine, aimed to highlight its proliferative effect on
dentate gyrus progenitor cells either alone or together with
the pro-differentiation and survival effects (see Supplementary
Table S1). In fact, we observe that while the neurogenic stimulus
by fluoxetine highly increases the absolute number of terminally
differentiated neurons (stage 6), relative to control-treated
wild-type or Tis21-null dentate gyrus, that stimulus is unable to
change the ratio of Tis21-null stage 6 neurons to the background
production of new neurons. This indicates that changes in
proliferation and/or in cell cycle length—as that observed in
Tis21 knockout progenitor cells after fluoxetine treatment—do
not interfere with the rate of differentiation once a genetic
impairment of the process is present. No significant influence
on the Tis21 differentiation defect is observed even when the
proliferative stimuli are coupled to paradigms favoring the
differentiation and survival by fluoxetine (Figure 3). However,
in an experiment highlighting both the proliferative and
differentiative effects of fluoxetine (Supplementary Figure S1),
the ratio of Tis21-null stage 5 neurons to the background
production of new neurons is rescued to almost normal values.
Thus, the increased amount of stage 5 neurons terminally
differentiates into stage 6, although this transition rate remains
slower than in normal neurons. This defect of terminal
differentiation is not rescued even by a neurogenic cognitive
stimulus, such as the training in a hippocampus-dependent
spatial memory task (Figure 4). We exploited this stimulus,
which induces the generation of new neurons in the dentate
gyrus, with a protocol aimed to specifically monitor the new
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neurons differentiated following the stimulus. As a whole,
this suggests that the efficiency of the process of terminal
differentiation is primarily dependent on the genetic control of
that specific step and is rather independent from stimuli that
trigger mainly the cellular division, despite these are likely to
impact on cohorts of genes involved not only in the proliferative
process but also in the first steps of differentiation (Julian et al.,
2016). Apparently, the rate of differentiation of a progenitor
cell that has attained the early postmitotic condition becomes
independent from the pre-existing proliferative control, but the
time required to attain such a condition may vary depending
on the proliferative state and on the differentiative condition
downstream.
Thus, it is not sufficient to merely enhance the amplification
of neural stem cells in order to generate new neurons, as shown,
for instance, by Artegiani et al. (2011) through induction of cyclin
D1, unless the cell is in a mode permissive for differentiation.
This view would also agree with the observation made in
spinal cord progenitor cells that forcing their proliferation, by
overexpression of cyclin D, does not alter the neuronal fate,
indicating that neuronal specification and differentiation are
controlled independently of cell cycle exit (Lobjois et al., 2008).
In contrast, the specific upregulation in Tis21-null
proliferating dentate gyrus progenitor cells of NeuroD2, or
the silencing of Id3 by retroviral infection, determine a specific
rescue of terminal differentiation of dentate gyrus neurons,
further indicating that amplification and differentiation of
neural progenitor cells are processes genetically separated.
This rescue also represents the first demonstration that
NeuroD2 or the silencing of Id3 are able to activate the
differentiation of dentate gyrus neurons.
We selected NeuroD2 as it is normally expressed in terminally
differentiated (stage 6) dentate gyrus neurons (Roybon et al.,
2009), concomitantly with Tis21 (Attardo et al., 2010). Thus,
we asked whether NeuroD2 could substitute for Tis21. It has
been previously shown that the induction of the expression of
NeuroD2 in Xenopus embryos and P19 embryonal carcinoma
cell line, as well as in embryonic stem cells, is sufficient to
induce neural differentiation (McCormick et al., 1996; Farah
et al., 2000; Sugimoto et al., 2009). Moreover, NeuroD2 is
expressed in the hippocampus where it is required for survival
of hippocampal neurons (Olson et al., 2001) and where it
inhibits REST, involved in differentiation (Ravanpay et al., 2010;
Kim et al., 2015). Interestingly, recently Richetin et al. (2015)
did not observe an increase in the number of differentiating
neurons in the adult dentate gyrus infected with a retrovirus
expressing NeuroD2, whereas an increase was observed for
NeuroD1-infected cells. It is possible that, in a system where
the NeuroD1 pro-differentiative action prevails, only specific
conditions—such as those occurring in the differentiation-
defective Tis21 knockout system—can reveal the stage-specific
pro-differentiative action of NeuroD2. Presently we do not know
whether Tis21 regulates NeuroD2, although one possibility is
that this occurs indirectly through Id3. Future studies will be
necessary to assess this point and whether also other mechanisms
or molecular partners are able to rescue the Tis21-dependent
defect of terminal differentiation.
Concerning Id3, the Id proteins have a helix-loop-helix
(HLH) dimerization domain but lack the DNA-binding domain
and sequester E proteins, thus preventing their association to
proneural basic HLH transcription factors, such as NeuroD1 or
NeuroD2, in this way inactivating them (Lyden et al., 1999;
Andres-Barquin et al., 2000; Yokota, 2001). In neural crest cells,
Id3 has been shown to positively control the proliferation of
neural cells, besides inhibiting their differentiation (Kee and
Bronner-Fraser, 2005).
We have previously shown that in dentate gyrus Id3 is
inhibited by Tis21, as the knockout of Tis21 greatly induces
Id3 expression in that region (Farioli-Vecchioli et al., 2009). This
increase of Id3 is determined by the binding of the Tis21 protein
to the Id3 promoter, and is associated with a significant decrease
of Calbindin, marker of the terminally differentiated dentate
gyrus neurons (Farioli-Vecchioli et al., 2009). Since we show
here that the silencing of Id3 rescues the defective differentiation
of progenitor cells of the dentate gyrus, this indicates that
Id3 controls their terminal differentiation pathway, and that
Id3 is effector of Tis21, being also transcriptionally regulated by
Tis21 (Farioli-Vecchioli et al., 2009). Furthermore, it is worth
noting that Id3 controls the differentiation also of neuroblasts of
the subventricular zone, since Id3 silencing rescues the defective
differentiation observed in Tis21-null neurospheres (Farioli-
Vecchioli et al., 2014a).
Altogether, our demonstration that the overexpression of
NeuroD2 or the silencing of Id3 is able to restore a condition of
defective differentiation is critical as it points to the possibility
to use these targets to treat neurodegenerative diseases where
defects of terminal differentiation of new dentate gyrus neurons
occur, such as in Alzheimer’s disease, as we have previously
proposed (Tirone et al., 2013). Accordingly, it has been recently
demonstrated that by enhancing the differentiation of dentate
gyrus progenitor cells through NeuroD1 overexpression it is
possible to counteract the memory defects in a mouse model
of Alzheimer’s disease (Richetin et al., 2015). Moreover, the
selective expression of NeuroD2 in stage 6 neurons would suggest
a specificity in targeting terminal differentiation higher than
that of NeuroD1, which is highly expressed at an earlier stage,
in immature neurons (Pleasure et al., 2000). These data also
suggest that NeuroD2 could be no less effective than NeuroD1 in
restoring the differentiative function in a neurodegenerative
condition.
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FIGURE S1 | Fluoxetine, administered with a protocol highlighting proliferation
and differentiation, rescues stage 5 but not stage 6 neurons defective for
terminal differentiation in Tis21 knockout mice. (A) Representative confocal
images (40×) showing stage 5 (BrdU+/Calretinin+/NeuN+; white arrowheads),
and stage 6 neurons, (BrdU+/Calretinin−/NeuN+), treated as described in (B).
Scale bar, 100 µm. (B) Two-month-old mice received five daily injection of
BrdU at the end of the fluoxetine treatment, followed by 10 days off treatment
to allow differentiation. (C) Quantification of the number of new 15-day-old
cells shows increase in Tis21-null dentate gyrus of stage 5 immature neurons
and decrease of terminally differentiated stage 6 neurons, relative to wild-type.
Fluoxetine increases both stage 5 and stage 6 neurons in wild-type and
Tis21 knockout dentate gyrus. Simple effects analysis: ∗p < 0.05, ∗∗p < 0.01,
or ∗∗∗p < 0.001; PLSD ANOVA test. Cell numbers in the dentate gyrus are
mean ± SEM of the analysis of four animals per group. (D) The ratio of stage
5 neurons to the total number of BrdU+ cells was restored by fluoxetine in
mutant cells to the values of wild-type cells; nevertheless, no rescue was
observed for fluoxetine-treated stage 6 mutant neurons that remained lower
than control. Simple effects analysis: NS, p > 0.05, ∗∗∗p < 0.001;
Mann-Whitney U test.
FIGURE S2 | Fluoxetine treatment induces after 7 days a significant increase
of the number of dentate gyrus progenitor cells in adult wild-type mice, as
detected following multiple BrdU injections. (A) Representative confocal
images (40× magnification) showing proliferating dentate gyrus progenitor
cells, labeled by BrdU (red), in mice treated as described in (B). Dotted lines
delimit the outer boundary of the granule cell layer. Scale bar, 100 µm.
(B) Two-month-old mice received five daily injection of BrdU at the beginning
of the fluoxetine treatment, which lasted 7 days. (C) Quantification of total
proliferating adult progenitor cells in wild-type dentate gyrus, measured as
BrdU+ cells. Cell numbers in the dentate gyrus are mean ±SEM of the
analysis of five animals per group. ∗p < 0.05; PLSD
ANOVA test.
FIGURE S3 | Morris water maze (MWM) escape latency in wild-type and
mutant mice. The MWM was performed as in Farioli-Vecchioli et al. (2009) with
minor modifications. In this task, mice learn across daily sessions to find a
hidden escape platform using extra-maze visual cues. Tis21KO and Tis21WT
mice (both groups, n = 5) performed equally in the task. Statistical analysis
(repeated measures ANOVA) showed a significant effect of training
(F(6,48) = 10.26; p < 0.0001), no significant effect of genotype (F(1,8) = 1.87;
p = 0.21) and no significant genotype × training interaction (F(6,48) = 0.93;
p = 0.48). Shown is the daily mean escape latency (seconds ± SEM), i.e., the
time animals spent to reach the hidden platform throughout the 7-day-long
training. V1 and V2 refer to the first two training sessions of day 1, carried out
with a visible platform to rule out mouse sensorimotor deficits (not included in
the analysis). Furthermore, no significant differences between groups were
detected in averaged swimming speed (p = 0.947, Student’s t test) and
thigmotaxis (p = 0.702 Student’s t test) during the whole training (data not
plotted).
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